Response assessment to erythropoietin-zeta (epo-alpha biosimilar) therapy in low-risk myelodysplastic syndromes

HIGHLIGHTS

• who: Calogero Vetro and colleagues from the Division of Hematology, AOU. Policlinico "G. Rodolico-San Marco", Catania, ItalyHematology Unit, Thrombosis and Hemostasis Reference Regional Center, University of Palermo have published the Article: Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes, in the Journal: (JOURNAL) of 20/01/2022
• what: In this prospective observational study, our group demonstrated that biosimilar erythropoietin effectively induces an erythroid response in low-risk MDS patients while maintaining a good safety profile, similar to that of the originator molecule.
• how: The Kaplan-Meier . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.